- Previous Close
3.3750 - Open
3.3500 - Bid 3.0000 x --
- Ask 3.2500 x --
- Day's Range
3.0375 - 3.3500 - 52 Week Range
2.2700 - 13.0000 - Volume
78,549 - Avg. Volume
544,035 - Market Cap (intraday)
8.186M - Beta (5Y Monthly) 1.69
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.00
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Cardiff, the United Kingdom.
www.vericidx.com19
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: VRCI.L
View MorePerformance Overview: VRCI.L
Trailing total returns as of 2/21/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VRCI.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VRCI.L
View MoreValuation Measures
Market Cap
7.58M
Enterprise Value
2.40M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.80
Price/Book (mrq)
0.97
Enterprise Value/Revenue
0.70
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-110.99%
Return on Assets (ttm)
-26.14%
Return on Equity (ttm)
-58.12%
Revenue (ttm)
4.33M
Net Income Avi to Common (ttm)
-4.81M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
7.01M
Total Debt/Equity (mrq)
4.65%
Levered Free Cash Flow (ttm)
-3.67M